Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Advertisement
Advertisement
Trending on AJMC
1
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5
